Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $950.03, giving the company a market capitalization of 98.82B. It carries a P/E multiple of 21.09 and pays a dividend yield of 0.39%.
On 2026-11-14, Regeneron(REGN) stock moved within a range of $942.00 to $966.21. With shares now at $950.03, the stock is trading +0.9% above its intraday low and -1.7% below the session's peak.
Trading activity shows a volume of 928.17K, compared to an average daily volume of 1.18M.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
REGN News
Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Phase 2 PINNACLE trial results showing its investigational antibody baloncibart reduces abnormal standing...
Regeneron (REGN) announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome, or POTS, evaluating baloncibart, a...
Analyst ratings
67%
of 30 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals (NASDAQ: REGN) updated its Phas...
Regeneron Pharmaceuticals reported first-in-human data for its investigational CIDEBsiRNA in MASLD, with a single subcutaneous dose showing dose-dependent liver...
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Regeneron. The associated price target remains the same with $1,030.00....
Regeneron Pharmaceuticals (REGN) has put its early liver disease program in the spotlight after first in human data showed that a single CIDEBsiRNA dose reduced...
It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...
Investors signalled that they were pleased with Regeneron Pharmaceuticals, Inc.'s ( ) most recent earnings report. This reaction by the market reaction is under...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.